The FDA launched an “Expedited Investigational New Drug Pilot” to speed up early U.S. clinical trials and reduce timelines from discovery to first-in-human studies. The initiative, part of Operation Trialblazer, aims to encourage more sponsor activity in the U.S. instead of relying on faster-start environments overseas. Under the pilot, the FDA will select up to 10 “qualified research institutions” to work with drug developers, enabling a “rolling review” approach as different parts of an IND submission are completed. Applications are due Oct. 30, and the agency expects to pair institutions and sponsors to test the expedited process. The FDA positioned the pilot as a response to sponsor complaints about uncertainty and time costs in transitioning from scientific discovery to initial clinical testing, and it cited comparative speed advantages in markets such as Australia and China. If scaled, the program could shift near-term R&D planning by moving first-in-human activity back toward U.S. sites, with potential knock-on effects for data collection, trial logistics, and regulatory predictability for early programs.